Trials / Withdrawn
WithdrawnNCT02263222
A Feasibility Dose-escalating Study of MDT-10013 for Acute Postoperative Pain Following Total Knee Arthroplasty
A Feasibility Dose-escalating Study to Evaluate the Tolerability and Systemic Exposure of MDT-10013 Plus Routine Care in the Treatment of Acute Postoperative Pain Following Total Knee Arthroplasty
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Medtronic Spinal and Biologics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label dose-escalating study to evaluate the tolerability and systemic exposure of MDT-10013 in men and women at least 18 years of age who are undergoing primary unilateral TKA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MDT-10013 |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2014-10-13
- Last updated
- 2016-06-07
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02263222. Inclusion in this directory is not an endorsement.